Tubulin polymerization-IN-85 

Tubulin polymerization-IN-85 (Compound C21) is a tubulin polymerization inhibitor (IC₅₀ = 1.59 μM) targeting the colchicine binding site. Tubulin polymerization-IN-85 can cause cancer cells G2/M phase arrest and induce apoptosis. Tubulin polymerization-IN-85 downregulates the expression of Bcl-2, Bcl-xl, Mcl-1, Cyclin B1, cdc25, cdc2 protein and upregulates P53, P21, Bad and Bax levels. Tubulin polymerization-IN-85 can be used for the research of cancer, such as cervical cancer^[1].

Tubulin polymerization-IN-85 shows anti-proliferative activity against HeLa, HepG2, MCF-7 and A549 cells with IC₅₀ values of 0.08, 0.21, 0.27 and 0.32 μM, while has low toxicity to normal renal epithelial 293T cells (IC₅₀ = 187 μM)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

397.45

C₂₀H₁₉N₃O₄S

COC1=C(OC)C(OC)=CC(CSC2=NN=C(C3=CNC4=C3C=CC=C4)O2)=C1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Yang B, et al. Design, synthesis, and biological evaluation of 2-(benzylthio)-5-(indol-3-yl)-1,3,4-oxadiazole derivatives as tubulin polymerization inhibitors with potential anti-cancer effects. Eur J Med Chem. 2026 Feb 5;303:118405.  [Content Brief]